Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

INVO Fertility (IVF) Preferred Shares (2023 - 2025)

Historic Preferred Shares for INVO Fertility (IVF) over the last 3 years, with Q3 2025 value amounting to $8.9 million.

  • INVO Fertility's Preferred Shares rose 4795.6% to $8.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.9 million, marking a year-over-year increase of 4795.6%. This contributed to the annual value of $30.4 million for FY2024, which is 40625.0% up from last year.
  • INVO Fertility's Preferred Shares amounted to $8.9 million in Q3 2025, which was up 4795.6% from $10.1 million recorded in Q2 2025.
  • Over the past 5 years, INVO Fertility's Preferred Shares peaked at $30.4 million during Q4 2024, and registered a low of $6.0 million during Q4 2023.
  • Over the past 3 years, INVO Fertility's median Preferred Shares value was $7.4 million (recorded in 2023), while the average stood at $13.0 million.
  • As far as peak fluctuations go, INVO Fertility's Preferred Shares surged by 40625.0% in 2024, and later soared by 4795.6% in 2025.
  • Over the past 3 years, INVO Fertility's Preferred Shares (Quarter) stood at $6.0 million in 2023, then surged by 406.25% to $30.4 million in 2024, then plummeted by 70.77% to $8.9 million in 2025.
  • Its Preferred Shares was $8.9 million in Q3 2025, compared to $10.1 million in Q2 2025 and $30.4 million in Q1 2025.